XNAS · Healthcare · Biotechnology
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 0.85 | 0.44 | -48.24% | $58.8M | ❌ Miss | -0.68% | +4.56% | — |
| 2026-03-03 | Q4 2025 | 1.25 | 1.12 | -10.40% | $69.8M | ❌ Miss | +1.48% | -13.87% | -16.63% |
| 2025-11-04 |
| Q3 2025 |
| 0.85 |
| 1.46 |
| +71.76% |
| $69.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | 1.63 | 3.28 | +101.23% | $101.7M | ✅ Beat | +4.79% | +42.41% | +65.55% |
| 2025-03-04 | Q4 2024 | 0.55 | 0.80 | +45.45% | $57.6M | ✅ Beat | -8.11% | -11.73% | -20.04% |
| 2024-11-07 | Q3 2024 | 0.06 | 0.70 | +1066.67% | $55.3M | ✅ Beat | +42.94% | +77.85% | +50.00% |
| 2024-08-06 | Q2 2024 | -0.29 | -0.06 | +79.31% | $36.8M | ✅ Beat | +5.79% | +35.80% | +43.73% |
| 2024-05-07 | Q1 2024 | -0.30 | -0.50 | -66.67% | $29.5M | ❌ Miss | -16.61% | -20.38% | -19.35% |
Showing last 8 quarters.